Thailand Pharmaceuticals and Healthcare Report Q4 2009
Business Monitor International, September 2009, Pages: 80
The Thailand Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Thailand's pharmaceuticals and healthcare industry
For the Q4 2009 update of the Thailand Pharmaceuticals & Healthcare Report, we have extended our forecasts for prescription pharmaceuticals, patented products, generic drugs and over-the-counter (OTC) medicines through to 2018. The South East Asian country’s US$3.52bn pharmaceutical market is projected to post a compound annual growth rate (CAGR) of 8.20% in local currency terms. Due to the strengthening of the baht over the next 10 years, the market will post a CAGR of 10.37% in US dollar terms. However, we must caution that there are significant risks to this optimistic forecast, primarily political instability.
In the Pharmaceutical Environment Ratings table for Q409, Thailand has improved by one position, from 10th to 9th, out of the 15 key markets surveyed in the Asia Pacific region. Thailand’s growing and ageing population represents a substantial commercial opportunity for drugmakers, although its controversial compulsory licensing scheme is deterring foreign investment.
Thailand’s reputation for over-medicating has been highlighted once again. During the swine flu outbreak in July 2009, it was announced that the country would import second-line antivirals, such as zanamivir, amantadine and rimantadine. These would be in addition to oseltamivir, which was increasingly associated with resistance to the H1N1 virus in other parts of the world. In the World Health Organization (WHO)’s study on oseltamivir resistance during the 2007-2008 flu season, Thailand was named as one of the countries with a high antiviral drug resistance rate.
The Burden of Disease Database (BoDD) reveals that Thailand will become unhealthier over the next 20 years. The number of disability-adjusted life years (DALYs) lost to non-communicable disease will increase from 6,518,798 in 2008 to 8,438,723 in 2030, a rise of 29%. Meanwhile, the number of DALYs lost to communicable disease will increase from 3,526,188 in 2008 to 5,303,347, a rise of 50%. The main driver of these increases is a growing and ageing population.
Thailand’s GDP is expected to contract by -4.5% in real terms during 2009, from THB9,103bn (US$267bn) to THB8,813bn (US$253bn). This means that both state and patients will have less money to spend on healthcare. Partial economic recovery is forecast for 2009/2010, with full growth returning the following year. Pharmaceutical sales will rebound slightly in 2010, but then slowly decrease over our 10- year forecast period. It must be noted however that Thailand’s projected growth is still one of the highest in our 71-market coverage universe, and above the average for Asia Pacific. By 2018, the value of annual pharmaceutical sales in Thailand will have reached just under US$10bn.
EXECUTIVE SUMMARY
SWOT ANALYSIS
Thailand Pharmaceutical And Healthcare Industry SWOT
Thailand Political SWOT
Thailand Economic SWOT
Thailand Business Environment SWOT
PHARMACEUTICAL BUSINESS ENVIRONMENT RATINGS
Table: Asia Pacific – Regional Pharmaceutical Business Environment Ratings For Q409
Limits of Potential Returns
Risks to Realisation of Returns
THAILAND – MARKET SUMMARY
REGULATORY REGIME
National Health Assembly Agenda Items
Intellectual Property Regime
IP Shortcomings
Counterfeit Drugs
Compulsory Licensing Regulatory Developments
Recent IP Developments
Pricing and Reimbursement
INDUSTRY TRENDS AND DEVELOPMENTS
Epidemiology
Healthcare System
Healthcare Insurance
Healthcare Financing
Medical Tourism
Traditional Medicines
Pharmaceutical Retail
Vaccine Sector
Recent Vaccines Sector Developments
Research and Development
Recent Research and Development Activities
Biosimilars
Clinical Trials
Medical Devices
INDUSTRY FORECAST SCENARIO
Overall Market Forecast
Table: Pharmaceutical Market Forecast, 2003-2013
Key Growth Factors – Industry
Table: Healthcare Expenditure Forecast 2003-2013
Key Growth Factors – Macroeconomic
Thailand - Economic Activity, 2005 – 2013
Prescription Drug Market Forecast
Table: Thailand – Prescription Market Indicators, Historical Data And Forecast (THBmn unless otherwise indicated)
Patented Product Market Forecast
Table: Thailand – Patented Product Market Indicators, Historical Data and Forecasts
Generic Drug Market Forecast
Table: Thailand – Generic Drug Market Indicators, Historical Data and Forecasts
OTC Medicine Market Forecast
Table: Thailand – OTC Medicine Market Indicators, Historical Data and Forecasts (THBmn unless otherwise indicated)
Pharmaceutical Trade Forecasts
Table: Thailand – Pharmaceutical Trade Indicators, Historical Data and Forecasts (US$mn)
Medical Device Market Forecast
Table: Thailand – Medical Device Market Indicators, Historical Data and Forecasts (US$mn unless otherwise stated)
Other Healthcare Data Forecasts
Table: Thailand – Other Health Indicators, Historical Data and Forecasts
Key Risks to BMI’s Forecast Scenario
COMPETITIVE LANDSCAPE
Recent Industry Developments
COMPANY PROFILES
Leading Multinational Manufacturers
Pfizer
Sanofi-Aventis
GlaxoSmithKline
Merck & Co
Domestic Manufacturer Profiles
Siam Pharmaceutical
Government Pharmaceutical Organisation (GPO)
Biolab
COUNTRY SNAPSHOT: THAILAND DEMOGRAPHIC DATA
Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education and Healthcare
Table: Education, 2002-2005
Table: Vital Statistics, 2005-2030
Section 3: Labour Market and Spending Power
Table: Employment Indicators, 2001-2006
Table: Consumer Expenditure, 2000-2012 (US$)
Table: Average Annual Non-Agricultural Wages, 2001-2012
BMI METHODOLOGY
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources
- Pfizer
- Sanofi-Aventis
- GlaxoSmithKline
- Merck & Co
- Domestic Manufacturer Profiles
- Siam Pharmaceutical
- Government Pharmaceutical Organisation (GPO)
- Biolab
Product Samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW6
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
